Search results for "Proinsulin"

showing 10 items of 19 documents

Unexpected subcellular distribution of a specific isoform of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic beta cells

2018

Aims/hypothesis: The Coxsackie and adenovirus receptor (CAR) is a transmembrane cell-adhesion protein that serves as an entry receptor for enteroviruses and may be essential for their ability to infect cells. Since enteroviral infection of beta cells has been implicated as a factor that could contribute to the development of type 1 diabetes, it is often assumed that CAR is displayed on the surface of human beta cells. However, CAR exists as multiple isoforms and it is not known whether all isoforms subserve similar physiological functions. In the present study, we have determined the profile of CAR isoforms present in human beta cells and monitored the subcellular localisation of the princi…

0301 basic medicineMaleviruksetEndocrinology Diabetes and MetabolismInsulin-Secreting CellsProtein IsoformsReceptorChildProinsulinEnterovirusMicroscopy ConfocalChemistryNuclear ProteinsImmunogold labellingMiddle AgedFlow CytometryImmunohistochemistryTransmembrane protein3. Good healthCell biologyEndocrinologieenteroviruksetMédecine interneProtein interacting with C-kinase 1 (PICK1)medicine.anatomical_structureChild PreschoolCoxsackievirus BFemalePancreasPICK1Gene isoformBeta cells; Coxsackie and adenovirus receptor; Coxsackievirus B; Enterovirus; Insulin granule; Pancreas; Protein interacting with C-kinase 1 (PICK1)AdultCoxsackie and Adenovirus Receptor-Like Membrane ProteinAdolescentImmunoprecipitationBlotting WesterninsuliiniArticle03 medical and health sciencesYoung AdultMétabolismeInternal MedicinemedicineHumansImmunoprecipitationPancreasCoxsackie and adenovirus receptorInsulin granuleDiabétologieBeta cellshaima030104 developmental biologyDiabetes Mellitus Type 1Carrier ProteinsDiabetologia
researchProduct

Preproinsulin designer antigens excluded from endoplasmic reticulum suppressed diabetes development in nod mice by dna vaccination

2019

DNA vaccines against autoimmune type 1 diabetes (T1D) contain a nonpredictable risk to induce autoreactive T cell responses rather than a protective immunity. Little is known if (and how) antigen expression and processing requirements favor the induction of autoreactive or protective immune responses by DNA immunization. Here, we analyzed whether structural properties of preproinsulin (ppins) variants and/or subcellular targeting of ppins designer antigens influence the priming of effector CD8+ T cell responses by DNA immunization. Primarily, we used H-2b RIP-B7.1 tg mice, expressing the co-stimulator molecule B7.1 in beta cells, to identify antigens that induce or fail to induce autoreacti…

0301 basic medicinepreproinsulin/proinsulin antigensPreproinsulinlcsh:QH426-470type 1 diabetesMouse ModelsBiologyMajor histocompatibility complexArticleDNA vaccinationDNA vaccines03 medical and health sciences0302 clinical medicineImmune systemAntigenImmunityGeneticsmouse models:Science::Medicine [DRNTU]lcsh:QH573-671Molecular BiologyNOD micelcsh:Cytologylcsh:Geneticsendoplasmic reticulum030104 developmental biology030220 oncology & carcinogenesisImmunologybiology.proteinType 1 DiabetesMolecular MedicineCD8
researchProduct

The Influence of Insulin on Local Amyloidosis of the Islets of Langerhans and Insulinoma

1980

Summary Amyloid-containing islets of Langerhans from the pancreas of 75 diabetics and one case of an amyloid-containing insulinoma were investigated. By light and electron microscopy, amyloid deposits were observed between the B cells and adjacent capillaries. The cytoplasm of B cells and extracellular amyloid display immunohistological binding of anti-insulin antibody. Correspondingly, ferritin-labeled anti-insulin antibody was found by electron microscopy on and between the amyloid fibrils. Insulin or proinsulin (or a protein closely related to insulin) thus appears to be a.component of the protein which constitutes the amyloid. The molecular weight and mode of deposition of this form of …

AdultMalemedicine.medical_specialtyAmyloidmedicine.medical_treatmentPathology and Forensic MedicineIslets of LangerhansInsulin-Secreting CellsInternal medicinemental disordersExtracellularmedicineHumansHypoglycemic AgentsInsulinInsulinomaAgedProinsulinAged 80 and overbiologyChemistryInsulinAmyloidosisAmyloidosisCell BiologyMiddle Agedmedicine.diseaseImmunohistochemistryPancreatic NeoplasmsMicroscopy Electronmedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 2biology.proteinFemaleInsulinomaAntibodyPancreasPathology - Research and Practice
researchProduct

Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus

2010

The aim of the present study was to compare the effect of PIO (pioglitazone) or GLIM (glimepiride) on erythrocyte deformability in T2DM (Type 2 diabetes mellitus). The study covered 23 metformin-treated T2DM patients with an HbA1c (glycated haemoglobin) >6.5%. Patients were randomized to receive either PIO (15 mg, twice a day) or GLIM (1 mg, twice a day) in combination with metformin (850 mg, twice a day) for 6 months. Blood samples were taken for the measurement of fasting glucose, HbA1c, fasting insulin, intact proinsulin, adiponectin and Hct (haematocrit). In addition, the erythrocyte EI (elongation index) was measured using laser diffractoscopy. Both treatments significantly impr…

AdultMalemedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentType 2 diabetesInsulin resistanceErythrocyte DeformabilityInternal medicineDiabetes mellitusHumansHypoglycemic AgentsMedicineAgedProinsulinGlycated HemoglobinPioglitazoneAdiponectinbusiness.industryInsulinnutritional and metabolic diseasesGeneral MedicineMiddle Agedmedicine.diseaseMetforminGlimepirideSulfonylurea CompoundsEndocrinologyDiabetes Mellitus Type 2Drug Therapy CombinationFemaleThiazolidinedionesStress MechanicalbusinessPioglitazonemedicine.drugClinical Science
researchProduct

Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving…

2017

Aims The aim of the study was to investigate the effect of sequential treatment escalation with empagliflozin and linagliptin on laboratory markers of alpha- and beta cell function in patients with type 2 diabetes mellitus (T2DM) insufficiently controlled on metformin monotherapy. Methods Forty-four patients with T2DM received 25 mg empagliflozin for a duration of one month in an open-label fashion (treatment period (TP 1). Thereafter, patients were randomised to a double-blind add-on therapy with linagliptin 5 mg or placebo (TP 2) for one additional month. Alpha- and beta cell function were assessed with a standardised liquid meal test (LMT) and an intravenous (iv.) glucose challenge. Effi…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismLinagliptinType 2 diabetes030204 cardiovascular system & hematologyLinagliptinGlucagon03 medical and health sciences0302 clinical medicineEndocrinologyDouble-Blind MethodGlucosidesInternal medicineInsulin-Secreting CellsInternal MedicinemedicineEmpagliflozinHumansHypoglycemic AgentsInsulinBenzhydryl CompoundsProinsulinAgedbusiness.industryInsulinMiddle Agedmedicine.diseaseGlucagonPostprandial PeriodMetforminEndocrinologyPostprandialTreatment OutcomeDiabetes Mellitus Type 2Glucagon-Secreting CellsGlucose Clamp TechniqueFemalebusinessmedicine.drugProinsulinDiabetes, obesitymetabolism
researchProduct

Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus

2012

This study compared the effect of Glimepiride versus Vildagliptin on β-cell function and the release of intact proinsulin (PI) in patients with type 2 diabetes mellitus. Patients on metformin monotherapy were randomized to add on treatment with Vildagliptin or Glimepiride. A standardized test meal was given at baseline, after 12 and 24 weeks of treatment. Insulin, PI and blood glucose values were measured in the fasting state and postprandial for 300 min. Fasting PI levels significantly decreased in the Vildagliptin group. The area under the curve for the postprandial release of PI decreased during Vildagliptin and increased during Glimepiride treatment. The proinsulin to insulin ratio decl…

Blood GlucoseMalemedicine.medical_specialtyPyrrolidinesendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdamantaneEndocrinologyDiabetes mellitusInternal medicineNitrilesInternal MedicinemedicineHumansHypoglycemic AgentsVildagliptinProinsulinVildagliptinDipeptidyl-Peptidase IV Inhibitorsbusiness.industryInsulinnutritional and metabolic diseasesType 2 Diabetes MellitusPostprandial Periodmedicine.diseaseMetforminMetforminGlimepirideSulfonylurea CompoundsTreatment OutcomePostprandialEndocrinologyDiabetes Mellitus Type 2Area Under CurveDrug Therapy CombinationFemalebusinessProinsulinmedicine.drugDiabetes, Obesity and Metabolism
researchProduct

Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide.

2003

There is increasing evidence for biological functions of human C-peptide. Recently, we have described that proinsulin C-peptide increases nutritive capillary blood flow and restores erythrocyte deformability in type 1 diabetic patients, whereas it has no such effect in non-diabetic subjects. The aim of the current study was to elucidate cellular mechanisms of this vasodilator effect in vitro by measuring the nitric oxide (NO)-mediated increase of cGMP production in a RFL-6 reporter cell assay and by demonstrating endothelial calcium influx with the Fluo-3 technique. C-peptide increased the release of NO from endothelial NO synthase (eNOS) in bovine aortic endothelial cells in a concentratio…

Cancer Researchmedicine.medical_specialtyArginineNitric Oxide Synthase Type IIIPhysiologyClinical BiochemistryBlotting WesternStimulationVasodilationBiologyNitric OxideBiochemistryNitroarginineNitric oxidechemistry.chemical_compoundEnosInternal medicinemedicineErythrocyte deformabilityAnimalsHumansEnzyme InhibitorsCyclic GMPProinsulinFluorescent DyesAniline CompoundsC-PeptideC-peptideReverse Transcriptase Polymerase Chain ReactionEndothelial Cellsbiology.organism_classificationEndocrinologychemistryMicroscopy FluorescenceXanthenesRNACalciumCattleNitric Oxide SynthaseNitric oxide : biology and chemistry
researchProduct

Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Trea…

2018

AbstractWe investigated the effect of sequential treatment escalation with dapagliflozin and saxagliptin on beta cell function in patients with T2DM insufficiently controlled on metformin monotherapy during a hyperglycaemic clamp investigation. Twenty-six patients (19 males, age 63.5±7.0 years; duration of diabetes 8.8±4.7 years; HbA1c 63.9±15.8 mmol/mol; mean±SD) were enrolled in the study. During a first treatment period (TP1) all patients received 10 mg dapagliflozin for one month, followed by the addition of 5 mg saxagliptin or placebo for another month (TP2). At baseline and at the end of each treatment period, fasting glucose and insulin levels were analysed, and a hyperglycaemic clam…

Malemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryAdamantane030209 endocrinology & metabolism030204 cardiovascular system & hematologySaxagliptinBiochemistryGlucagon03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInsulin resistanceDouble-Blind MethodGlucosidesInsulin-Secreting CellsInternal medicineDiabetes mellitusmedicineHumansBenzhydryl CompoundsDapagliflozinAgedProinsulinbusiness.industryInsulinBiochemistry (medical)DipeptidesGeneral MedicineMiddle Agedmedicine.diseaseMetforminEndocrinologyDiabetes Mellitus Type 2chemistryFemalebusinessmedicine.drugHormone and Metabolic Research
researchProduct

Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β-cell protection in individuals with type 2 diabetes

2010

AIM Postprandial release of intact proinsulin (IP) is an independent marker for beta-cell dysfunction in patients with type 2 diabetes. This open-label, parallel-group, two-arm, pilot study compared the beta-cell protective effect of adding insulin glargine (GLA) vs. NPH insulin to ongoing metformin. MATERIAL AND METHODS Overall, 28 insulin-naive type 2 diabetes subjects (mean +/- SD age, 61.5 +/- 6.7 years; diabetes duration, 9.8 +/- 6.5 years; HbA1c, 7.1 +/- 0.5%; BMI, 30.7 +/- 4.3 kg/m(2)) treated with metformin and sulfonylurea were randomized to add once-daily GLA or NPH at bedtime. At baseline and after 3 months, subjects received a standardized breakfast, lunch and dinner, with pre- …

Malemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentInsulin IsophaneInsulin GlarginePilot ProjectsNPH insulinType 2 diabetesNPH insulinDrug Administration ScheduleEndocrinologyInsulin-Secreting CellsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsInsulinintact proinsulinGlycated Hemoglobinbusiness.industryInsulin glargineInsulindigestive oral and skin physiologynutritional and metabolic diseasesFastingOriginal ArticlesMiddle AgedPostprandial Periodmedicine.diseaseMetforminMetforminInsulin Long-ActingEndocrinologyPostprandialDiabetes Mellitus Type 2beta cell stressDrug Therapy CombinationFemalebusinessmedicine.drugBlood samplingDiabetes, Obesity and Metabolism
researchProduct

In Vitro Generation of Pancreatic Endocrine Cells from Human Adult Fibroblast-Like Limbal Stem Cells

2012

Stem cells might provide unlimited supply of transplantable cells for β-cell replacement therapy in diabetes. The human limbus is a highly specialized region hosting a well-recognized population of epithelial stem cells, which sustain the continuous renewal of the cornea, and the recently identified stromal fibroblast-like stem cells (f-LSCs), with apparent broader plasticity. However, the lack of specific molecular markers for the identification of the multipotent limbal subpopulation has so far limited the investigation of their differentiation potential. In this study we show that the human limbus contains uncommitted cells that could be potentially harnessed for the treatment of diabete…

Pluripotent Stem CellsStromal cellCellular differentiationPopulationBiomedical Engineeringlcsh:MedicineEnteroendocrine cellLimbus CorneaeBiologyLimbus; β-CellsSettore MED/13 - EndocrinologiaLimbuInsulin-Secreting CellsInsulin SecretionDiabetes MellitusHumansInsulineducationInduced pluripotent stem cellCells CulturedProinsulinTransplantationeducation.field_of_studyDiabeteslcsh:RCell DifferentiationCell Biologyβ-CellsCell biologyAdult Stem CellsStem cellFibroblast-like stem cellsBiomarkersAdult stem cellCell Transplantation
researchProduct